This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| Item | Details |
|---|---|
| A. Classification codes | ICD-10: L40.3 | Special Copayment Reduction: V313 (rare disease) |
| B. Synonyms | — |
| C. Adult onset | Likelihood of first onset in adulthood very high — palmoplantar pustulosis typically first occurs in adults in their 40s–60s, especially women who smoke. Onset in children is very rare, and adult onset is an essential characteristic. |
| 1. History | Palmoplantar pustulosis (Pustulosis Palmaris et Plantaris, PPP; also called palmoplantar pustulosis) is confined to the palms and soles… |
| 2. Causes | The etiology of palmoplantar pustulosis has not been fully elucidated, but chronic immune activation around the eccrine sweat ducts has been proposed as the key mechanism. In lesion biopsies, eccrine sweat duct… |
| 3. Genetics | Palmoplantar pustulosis is a complex genetic disease; psoriasis-related genes (particularly HLA-Cw6 at the PSORS1 locus) are associated in some patients, but generalized plaque psoriasis… |
| 4. General epidemiology | The prevalence of palmoplantar pustulosis is estimated at about 10–40 per 1 million population, with regional variation. Epidemiologic data from Sweden, Japan and the United Kingdom are relatively… |
| 5. Pathophysiology | In the pathophysiology of palmoplantar pustulosis, the eccrine sweat duct and its surrounding immune environment play a key role. Early in the lesion, eccrine… |
| 6. Symptoms | The main symptoms of palmoplantar pustulosis are recurrent sterile pustules confined to the palms and soles, with resulting pain and fissures. Early in the lesion, small (1–5 mm) yellow… |
| 7. Signs | As physical signs of palmoplantar pustulosis, on an erythematous background on the palms and soles, sterile pustules at various stages (fresh yellowish-white pustules, brown dried pustules), scaling,… |
| 8. Screening | Screening for palmoplantar pustulosis is done in patients with recurrent pustular eruptions and fissures on the palms and soles. To exclude fungal infections (tinea pedis, candidiasis), KOH… |
| 9. Diagnosis | Diagnosis of palmoplantar pustulosis relies most on clinical findings and is confirmed by biopsy. The diagnostic criteria are ① recurrent pustules confined to the palms and/or soles, ② bacterial… |
| 10. Treatment | In the treatment of palmoplantar pustulosis, smoking cessation is the most important first-line treatment strategy. After smoking cessation, some patients show significant improvement or… |
| 11. Prognosis | Palmoplantar pustulosis shows a chronic relapsing course, and complete remission is often difficult. A considerable proportion improve after smoking cessation, but patients reaching complete remission… |
| 12. Prevention | The key to preventing palmoplantar pustulosis is smoking cessation and avoidance of triggering factors. Smoking cessation counseling and pharmacologically assisted smoking cessation treatment are actively provided. Recurrent foci of infection such as tonsillitis… |
| 13. References | 10 papers in major international journals. |
Palmoplantar pustulosis (Pustulosis Palmaris et Plantaris, PPP; also called palmoplantar pustulosis) is a chronic inflammatory skin disease in which sterile pustules occur repeatedly, confined to the palms and soles. Historically, European dermatologists in the late 19th century began describing pustular skin lesions of the palms and soles, but at first these were regarded as part or a localized form of psoriasis.
Until the mid-20th century, debate continued over the relationship of PPP to psoriasis. Some scholars classified PPP as localized pustular psoriasis (palmoplantar pustular psoriasis), and others as an independent inflammatory skin disease unrelated to psoriasis. Current international consensus recognizes PPP as a distinct independent disease entity that partly overlaps with psoriasis. The European Reference Network for rare skin autoinflammatory diseases (ERN-Skin) classifies PPP as a disease separate from generalized pustular psoriasis.
In recent studies, the IL-17 and IL-36 signaling pathways and immune responses around the eccrine sweat glands have attracted attention as the key pathogenesis of PPP. Smoking is established as the strongest risk factor for PPP, and the hypothesis has been proposed that immune activation around the eccrine sweat ducts of smokers induces pustule formation. As a joint complication, osteoarticular inflammation including sternoclavicular arthropathy (SAPHO syndrome) accompanies the disease in some patients.
The etiology of palmoplantar pustulosis has not been fully elucidated, but chronic immune activation around the eccrine sweat ducts has been proposed as the key mechanism. In lesion biopsies, prominent T-cell (CD4+, CD8+) and neutrophil infiltration around the eccrine sweat ducts is observed. IL-17A, IL-17F, IL-22 and IL-36 cytokines are upregulated in lesional skin. Secretion of CXC chemokines such as IL-8 (CXCL8) and CXCL1 by keratinocytes increases, recruiting neutrophils around the eccrine sweat ducts. The recruited neutrophils form sterile pustules within the ducts or the epidermis.
Smoking is the strongest and most consistent risk factor for PPP, with 70–90% of patients being current or former smokers. As a mechanism by which smoking activates immune responses around the eccrine sweat ducts, there is a hypothesis that activation of cholinergic receptors (α9nAChR) by nicotine stimulates eccrine sweat duct cells to induce IL-17 secretion. There are also observations that focal infections such as tonsillitis and odontogenic infections are associated with the induction or exacerbation of PPP, and cases of PPP improving after tonsillectomy have been reported. Some drugs (lithium, paradoxical reactions to anti-TNF agents) can also induce PPP. Thyroid dysfunction, sternoclavicular arthropathy and osteoarticular inflammation are also recognized as associated conditions.
Palmoplantar pustulosis is a complex genetic disease; psoriasis-related genes (particularly HLA-Cw6 at the PSORS1 locus) are associated in some patients, but the association is weaker than in generalized plaque psoriasis. The proportion of HLA-Cw6-negative patients is higher in PPP, suggesting that the genetic backgrounds of the two diseases differ. Recently, IL36RN variants have been found in some PPP patients, raising the question of continuity or shared pathogenesis with generalized pustular psoriasis. CARD14 gain-of-function variants have also been reported in some PPP-related cases. Overall, research on genetic risk factors for PPP is less extensive than for generalized psoriasis, and GWAS-scale studies are needed.
The prevalence of palmoplantar pustulosis is estimated at about 10–40 per 1 million population, with regional variation. Epidemiologic data are relatively well compiled in Sweden, Japan and the United Kingdom. The age of onset is mainly the 40s–60s, and it is more common in women (female:male = about 3–4:1). Women with a smoking history are the highest-risk group. There are reports that the proportion of PPP among psoriasis outpatients is considerable in East Asia, including Korea. There are also paradoxical cases in which PPP improves or newly develops after smoking cessation, suggesting the complexity of the smoking-PPP relationship. In SAPHO syndrome (Synovitis, Acne, Pustulosis, Hyperostosis, Osteitis), PPP is the essential skin component, appearing in over 90% of SAPHO patients.
In the pathophysiology of palmoplantar pustulosis, the eccrine sweat duct and its surrounding immune environment play a key role. Early in the lesion, T-cell and neutrophil infiltration begins around the eccrine sweat ducts, and ductal epithelial cells are activated to secrete CXCL8 and other chemotactic molecules. As a result, neutrophils migrate around the ducts and into the epidermis, forming sterile pustules within the epidermis. Cooperative IL-17 and IL-36 signaling amplifies this process. The palms and soles are the body sites with the highest density of eccrine sweat glands, which explains the localized distribution of PPP.
A proposed mechanism is that nicotine from smoking activates nicotinic acetylcholine receptors (particularly α9nAChR) on eccrine sweat duct cells, inducing IL-17 secretion by the duct cells. A mechanism has also been proposed in which immune responses to local bacteria (particularly streptococci) arising from the tonsils or dental foci spread to the skin and induce IL-17-mediated eccrine sweat gland inflammation. In SAPHO syndrome, bacterial colonization of the eccrine glands (biofilm) and immune overactivation by bacterial antigens have been hypothesized as the mechanism linking PPP and osteoarticular inflammation.
The main symptoms of palmoplantar pustulosis are recurrent sterile pustules confined to the palms and soles, with resulting pain and fissures. Early in the lesion, small (1–5 mm) yellowish-white pustules arise on an erythematous background and then turn brown to dark brown and dry into scales. Fissures develop where the dried scales peel off, accompanied by pain and bleeding. Lesions are particularly common on the thenar eminence of the palm, the hypothenar eminence and the arch of the sole. Nail involvement (psoriatic nails) accompanies the disease in about 30–40%.
Joint symptoms such as sternoclavicular arthritis, sternal pain and spinal osteoarthritis (SAPHO) may be present. Painful pustules and fissures cause walking difficulty and impaired hand function, seriously affecting occupational activity, daily life and social participation. The reduction in quality of life is as severe as that of extensive plaque psoriasis. Repeated relapses are characteristic, with a chronic course of alternating improvement and exacerbation.
As physical signs of palmoplantar pustulosis, sterile pustules at various stages (fresh yellowish-white pustules, brown dried pustules), scaling and fissures are observed on an erythematous background on the palms and soles. Lesion borders are relatively well defined and confined to the palms and soles. The Nikolsky sign is negative. Nail examination may show dystrophic nails (pitting, yellowing, onycholysis). If there are osteoarticular symptoms such as sternoclavicular tenderness or tenderness of the spinal joints, the possibility of SAPHO is evaluated. Laboratory tests may show negative pustule cultures, elevated serum CRP (when SAPHO is present) and abnormal thyroid function tests. On skin biopsy, T-cell and neutrophil infiltration around the eccrine sweat ducts and intraepidermal sterile pustules are characteristic.
Screening for palmoplantar pustulosis is done in patients with recurrent pustular eruptions and fissures on the palms and soles. KOH examination and fungal culture to exclude fungal infections (tinea pedis, candidiasis) are important. Bacterial culture confirms that the pustules are sterile. Psoriasis assessment (generalized psoriatic lesions, PASI score, nail PSI) is performed concurrently to differentiate from psoriasis and evaluate co-occurrence. Checking smoking history is essential. When SAPHO is suspected, sternoclavicular radiography and a bone scan are performed. When lesions are unilateral or atypical, the diagnosis is confirmed by skin biopsy. Thyroid function tests and evaluation for tonsillar infection may also be included.
Diagnosis of palmoplantar pustulosis relies most on clinical findings and is confirmed by biopsy. The diagnostic criteria are ① recurrent pustules confined to the palms and/or soles, ② negative bacterial cultures and ③ histopathology: intraepidermal sterile pustules (infiltration around the eccrine sweat ducts). Supportively, smoking history, thyroid dysfunction, tonsillitis and joint symptoms (SAPHO) contribute to diagnostic certainty. Differentiation from generalized pustular psoriasis (L40.1) is based on whether the lesions are confined to the palms and soles and whether generalized pustules and fever are absent. Differential diagnoses such as fungal infection (tinea pedis, dyshidrotic eczema, dermatitis) are excluded by KOH examination, biopsy and culture.
In the treatment of palmoplantar pustulosis, smoking cessation is the most important first-line treatment strategy. Significant improvement or remission after smoking cessation has been reported in some patients. Topical treatment: potent topical corticosteroids (class I), calcipotriol, tazarotene and topical retinoids are used. Phototherapy: narrowband ultraviolet B (nbUVB), excimer laser and PUVA (psoralen + UVA) are effective. Systemic treatment: acitretin (first choice), apremilast (PDE4 inhibitor) and cyclosporine are used in moderate to severe disease. Biologics: secukinumab (IL-17A blockade), ixekizumab (IL-17A blockade), benralizumab (eosinophil-targeted) and others are in clinical trials for PPP. When a tonsillar focus is identified, tonsillectomy has been reported to be effective in improving PPP in some patients.
Palmoplantar pustulosis shows a chronic relapsing course, and complete remission is often difficult. A considerable proportion improve after smoking cessation, but only a minority of patients reach complete remission. Partial or complete remission has been reported in about 40–60% with acitretin and phototherapy. Randomized controlled trials of biologics (anti-IL-17 class) in PPP have confirmed some efficacy, but response rates are lower than in plaque psoriasis. Patients with SAPHO must also have their osteoarticular symptoms managed. Because the reduction in quality of life is severe, there are long-term effects on work performance and social participation. Psychological support (risk of accompanying depression and anxiety) and active pain management should also be included in the treatment plan.
The key to preventing palmoplantar pustulosis is smoking cessation and avoidance of triggering factors. Smoking cessation counseling and pharmacologically assisted smoking cessation treatment are actively provided. When there are recurrent foci of infection such as tonsillitis, otolaryngology evaluation and tonsillectomy are considered. Local irritation (strong friction, ill-fitting shoes) is avoided, and skin moisturizing and protection are strengthened. In patients taking lithium, β-blockers or drugs that can cause paradoxical anti-TNF reactions, drug adjustment is reviewed when PPP develops. Maintenance treatment (acitretin, apremilast, phototherapy) reduces the frequency of relapse. Treatment effects and adverse effects are monitored with regular dermatology follow-up.